SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8, IN PATIENTS WITH EOSINOPHILIC GASTRITIS/DUODENITIS

Evan S. Dellon  ¹     Kathryn Peterson  ²     Nirmala Gonsalves  ³     Robert Genta  ⁴     John Leung  ⁵     Paneez Khoury  ⁶     Amy Klion  ⁶     Sabine Hazan  ⁷     Adam Bledsoe  ⁸     Sandy Durrani  ⁹     Chao Wang  ¹⁰     Camilla Shaw  ¹¹     Alan Chang  ¹¹     BHUPINDER SINGH  ¹¹     Amol Kamboj  ¹¹     Henrik Rasmussen  ¹¹     Ikuo Hirano  ¹¹     Mirna Chehade  ¹²     Joseph Murray  ¹²     Gary W. Falk  ¹³     Michael F. Vaezi  ¹⁴     Marc E. Rothenberg  ^14    
1 University of North Carolina, Chapel Hill, United States
² University of Utah, Salt Lake City, United States
³ Northwestern University, Chicago, United States
⁴ Baylor College of Medicine, Houston, United States
⁵ Tufts University, Boston, United States
⁶ NIAID/NIH, Bethesda, United States
⁷ Ventura Clinical Trials, Ventura, United States
⁸ Mayo Clinic Rochester, Rochester, United States
⁹ Cincinnati Children’s Hospital, University of Cincinnati College of Medicine, Cincinnati, United States
¹⁰ Pharma Data Associates, Piscataway, United States
¹¹ Allakos, Inc., Redwood City, United States
¹² Icahn School of Medicine at Mount Sinai, New York, United States
¹³ University of Pennsylvania Perelman School of Medicine, Philadelphia, United States
¹⁴ Vanderbilt University, Nashville, United States

Topic
Immunology, Oesophagus, Paediatrics

Session
Eosinophilic oesophagitis: The essential

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)